



Compassionate
Oncology Medical Group

Bob Leibowitz, M.D.

DIPLOMATE
AMERICAN BOARDS OF INTERNAL MEDICINE
AND SUBSPECIALTIES OF
MEDICAL ONCOLOGY AND HEMATOLOGY

Bob Leibowitz, M.D. a.k.a. “Dr. Bob”

In the 1960's, the University of Illinois Medical School had an accelerated admissions program that allowed a small number of honor college students to be admitted to medical school after three years of undergraduate study. Dr. Bob was one of these fortunate few who were permitted to complete college and medical school requirements in seven years instead of the normal eight years. However, in order to graduate from college, three years of a foreign language were required. Alas, Dr. Bob had only taken two years of German. As a result of this anomaly, he never graduated from college, although he did graduate from medical school. Imagine what he might have made of himself had he not been a college drop out.

He was elected to Alpha Omega Alpha (AOA) National Honors Medical Society while still in medical school. He graduated “with honors” from the University of Illinois Medical School (only about ten out of over 210 students were so honored) and delivered his medical school graduation (protest) speech. Hey, it was 1970. (Most of the faculty has still not forgiven him).

Following graduation from medical school, he did his straight medical internship and two years of medical residency at Rush Presbyterian-St. Luke's Medical Center in Chicago, Illinois. While an intern, he authored the hospital's first ever house-staff contract. After completing his residency, Dr. Bob's academic dreams became reality when he was appointed Research Fellow in Medicine at Harvard Medical School. He spent his Hematology fellowship at Peter Bent Brigham and Beth Israel Hospitals. During his second year he was appointed the first ever Oncology Fellow at Beth Israel Medical Center, one of only four Harvard affiliated hospitals, the others being Peter Bent Brigham (affectionately referred to as The Bent Peter Hospital by some), Massachusetts General, and Boston City Hospital.

Dr. Bob is the Father of Triple Hormone Blockade® (THB) and Finasteride Maintenance® (Proscar) therapy. He coined these terms and pioneered this unique, noninvasive treatment option for men presenting with clinically localized prostate cancer. He has been treating his patients with this protocol since 1991. He pioneered and was the first to use low-dose Taxotere/Emcyt/carboplatinum chemotherapy three weeks on, one week off for patients requiring chemotherapy. Unlike the typical side effects that most types of chemotherapy cause, this regimen is extremely well tolerated. Call our office and request a list of our patient volunteers (over 70 men to choose from) who are available to discuss their experiences when they were treated with our various treatment protocols.

Dr. Bob pioneered use of an Antiangiogenic Cocktail to help postpone or prevent the need to restart another cycle of Hormone Blockade. His most controversial, unique, flamboyant, successful, and current special area of investigation is using High-Dose Testosterone Replacement Therapy in men previously treated for prostate cancer.

His full-time clinical practice in Los Angeles is limited to treating patients with prostate cancer. Dr. Bob was advised by a mentor to:

“Pick one disease, study it well, and it will carry you to the ends of the earth.”

If you have prostate cancer and consult with Dr. Bob and Compassionate Oncology, you will be pleased and happy that Dr. Bob chose prostate cancer as the disease he devotes his energies and skills discovering unique, highly successful treatment protocols.

As always --

Be happy,

Be well,

Live long and prosper,

Dr. Bob